Study: Single Mutation Defeats AN3661 But AN7973 Still Works

A single change in one parasite protein is enough to defeat the leading experimental drug against Cryptosporidium parvum — but a second compound still works, researchers report in PLOS Neglected Tropical Diseases on Wednesday.

The study shows that a point mutation called Y385N in the parasite enzyme CPSF3 confers strong resistance to the benzoxaborole compound AN3661. Susceptibility to two related compounds, AN13762 and AN7973, remains intact. Cryptosporidiosis, the diarrheal disease the parasite causes, hits young children and neonatal livestock hardest, and therapeutic options remain severely constrained, the authors write.

The team used CRISPR-Cas9 genome editing to introduce targeted point mutations into the CPSF3 locus. That created a transgenic C. parvum line designated Cp-INRAE-Nluc-CPSF3Y385N, in which the Y385N substitution sits at the endogenous locus, the paper describes. Nanopore sequencing then showed how exposure to each benzoxaborole altered mRNA processing inside the parasite, and imaging-based quantification traced growth and developmental progression in cell culture.

CPSF3 is the parasite’s cleavage and polyadenylation specificity factor 3, an endonuclease that cuts RNA during pre-mRNA processing. Earlier work had already established — as the study notes — that AN3661 blocks this machinery in Cryptosporidium hominis and thereby curbs parasite proliferation. What was unresolved was whether resistance to one benzoxaborole would extend to the whole class.

Study: Single Mutation Defeats AN3661 But AN7973 Still Works
Photo: dx.plos.org

The genetic answer is narrow. Introducing Y385N produced high-level resistance specifically against AN3661; it did not diminish susceptibility to AN13762 or AN7973, even though both were also suspected of targeting the same endonuclease. All three compounds still disrupted CPSF-mediated mRNA processing and killed parasites directly, according to Bioengineer’s report on the findings.

Timing matters as well. The inhibitory effects fell predominantly during the late-stage maturation of first-generation meronts, blocking the parasite’s exit from infected host cells. Two of the three compounds also impaired gametogenesis, the parasite’s sexual development stage.

Animal work underpinned the claim that AN7973 can cover for a failed first choice. In the published figure data, mice infected with the resistant mutant received AN3661 in drinking water from day 3 post-infection, then were switched to AN7973 at 15 mg/kg from day 11 onward. Scanning electron microscopy of the ileum showed total parasite clearance in both treated groups.

Experiment Mice Infection dose Treatment
Dose-finding for AN3661 4 groups of 3 mice 5 × 10⁶ oocysts 0.8, 4 or 20 mg/kg in drinking water, from day 3 post-infection
Resistance comparison 2 groups of 5 GKO mice infection 3 days before treatment start 30 mg/kg AN3661, then 15 mg/kg AN7973 from day 11

The activity profile reaches beyond C. parvum. AN7973 kept working against Toxoplasma gondii strains resistant to both AN3661 and AN13762, which the authors read as evidence of a distinct mechanism. Eimeria tenella proved susceptible to both AN3661 and AN7973, and AN3661 retained activity against the gut parasite Giardia duodenalis.

For readers wondering why a livestock-grade parasite matters clinically, context from earlier coverage helps: cryptosporidiosis is a leading cause of death among children worldwide, and the only existing medication, nitazoxanide, has limited approval and efficacy in immunocompromised patients and malnourished children, according to a 2024 Medicalxpress report. No vaccine available.

The study, authored by researchers including J. Wenker and colleagues, is published in PLOS Neglected Tropical Diseases, volume 20, issue 11, as article e0014883.

What the work leaves out is harder: whether AN7973 can clear infection in immunocompromised patients at tolerable doses is a question no laboratory mouse experiment in the paper settles.

Earlier coverage: Computer-Aided Design Identifies New LaArg Inhibitors for Leishmaniasis

Photo of author

Technology Desk

Technology Desk at Archyde.

Casa Feliz Leads Tuesday Morning Ratings as TVI Loses Top Spot